Medtronic received European clearance for the Sentrino, a minimally invasive continuous glucometer for critical care units that are looking to provide high glycemic control.
The system displays the latest reading as well as a historic curve, triggering alarms when certain values are reached. Medtronic believes that the system’s ability to predict glucose levels will help clinicians intervene preemptively and reduce dangerous hypoglycemic events. The Sentrino is currently an investigational device in the U.S. and is not available for sale.
It enables clinicians to transition to an event-based protocol from a time-based measurement protocol, which is the current standard of care with blood glucose measurements taken every two-to-four hours.
The Sentrino CGM System was designed to address the unique needs of critical care patients with a highly innovative design and unique ability to integrate into clinical protocols including:
- Redundant sensing technology that optimizes signal reliability for more accurate visibility of glycemic variability.
- A minimally invasive, subcutaneous sensor customized for the critical care patient and inserts quickly and easily with low complication rates.
- A novel drug interference rejection technology that ensures minimal interference with the wide array of pharmaceuticals used in the critical care unit.
- An easily configurable system that integrates simply into clinical workflow.
Press release: Medtronic Sentrino® CGM System Gains CE Mark
